Status:
COMPLETED
A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP
Lead Sponsor:
Shandong University
Collaborating Sponsors:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Anhui Medical University
Conditions:
Thrombocytopenia
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
Brief Summary
Eltrombopag is an oral thrombopoietin receptor agonist that has been licensed for use as second line therapy in ITP patients. Diacerein is a slow-acting medicine of the class anthraquinone used to tre...
Detailed Description
The investigators are undertaking a prospective, open, multicentre trial of 30 ITP adult patients with eltrombopag-inefficient or relapsed from 6 medical centers in China. The initial dose of eltrombo...
Eligibility Criteria
Inclusion
- ITP patients with eltrombopag-inefficient or relapsed need of treatment(s) to minimize the risk of clinically significant bleeding primary ITP confirmed by excluding other supervened causes of thrombocytopenia
Exclusion
- pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment HCV, HIV, HBsAg seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03754634
Start Date
May 1 2019
End Date
November 1 2020
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hospital, Shandong University
Jinan, Shandong, China